5 reasons to attend the European Oncology Convention

On 6 & 7 June, 2018, London’s ExCeL will play host to the two most important days of the year for Europe’s leading oncology professionals...
SEE MORE

NHS cancer services facing nurse shortage

NHS hospitals in England are facing widespread shortages of specialist nurses, with over 400 vacancies...
SEE MORE

NHS prepared to fast-track CAR-T therapy

The treatment which works by genetically engineering a patient’s killer T-cells to recognise and destroy cancer cells...
SEE MORE

Agreement reached between Prysm Medical and Philips Healthcare

One-year agreement with UK’s largest medical exhibition on 6th & 7th June at ExCeL, London Philips become headline sponsor of European Neuro Convention, Medical Imaging Convention and European Oncology Convention ...
SEE MORE

People with breast cancer report fewer side effects using radiotherapy

Latest research show that over half of study participants did not report moderate side effects during five years after radiotherapy....
SEE MORE

Breast cancer tests vary in accuracy

Four tests used to predict if breast cancer would return 0-10 or 5-10 years after diagnosis vary in accuracy....
SEE MORE

Cancer Research UK and The Institute of Cancer Research announce partnership with Merck

New partnership aims to discover and develop new anticancer drugs....
SEE MORE

Are we one-step-closer to a universal blood test for cancer?

Researchers at John Hopkins University has trialled a method that can detect eight common forms of the disease....
SEE MORE

Researchers capture ‘incredible’ images of DNA that could help with cancer

Cyro-electron micropscopy captures RNA polymerase III....
SEE MORE

Who are The Swallows?

Find out more about our new show partner The Swallows...
SEE MORE

Patients five times more likely to avoid chemotherapy with early diagnosis

This new research is the first-time scientists have been able to show the link between the type of treatment NHS patients received and their cancer stage....
SEE MORE

Nivolumab available to hundreds of patients with head and neck cancer

The use of Nivolumab is recommended for use in the Cancer Drugs Fund (CDF) for patients with head and neck cancer who have not responded to chemotherapy within 6 months and whose cancer has spread to...
SEE MORE